Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study
Recruitment to an N-of-1 trial for xerostomia is feasible but attrition was high (50%). Early dropout may have been due to the trial length, complexity, appropriateness or number of questionnaires. Adverse events were generally mild. Two of 10 participants were considered to have benefited from pilocarpine warranting ongoing treatment.
Authors
- Rose Estafanos (ORCID: https://orcid.org/0000-0002-2186-4444)
- Hugh Senior (ORCID: https://orcid.org/0000-0002-7081-2499)
- Geoffrey Mitchell (ORCID: https://orcid.org/0000-0001-7817-6821)
- Karyn Foster (ORCID: https://orcid.org/0000-0002-7525-1547)
- Egessa Bwire Richard
- Kathryn J. Steadman (ORCID: https://orcid.org/0000-0001-7357-330X)
- Janet Hardy (ORCID: https://orcid.org/0000-0003-1127-9951)
Institutions
- The University of Queensland (AU)
- Mater Misericordiae Hospital (AU)
- Mater Research (AU)
- Massey University (NZ)
Publication Details
- Journal
- Palliative Medicine
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1177/02692163241306269
- Citations
- 1
- Primary Topic
- Salivary Gland Disorders and Functions
- Type
- article
- Field-Weighted Citation Impact
- 0.33
Funders
- Mater Foundation